glaxosmithkline research & development limited
glaxosmithkline research & development limited Company Information
Company Number
00835139
Website
http://gsk.comRegistered Address
79 new oxford street, london, WC1A 1DG
Industry
Other research and experimental development on natural sciences and engineering
Telephone
02080475000
Next Accounts Due
September 2025
Group Structure
View All
Shareholders
glaxo group ltd 100%
glaxosmithkline research & development limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED at £3.7b based on a Turnover of £1.5b and 2.55x industry multiple (adjusted for size and gross margin).
glaxosmithkline research & development limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED at £2.2b based on an EBITDA of £197m and a 11.23x industry multiple (adjusted for size and gross margin).
glaxosmithkline research & development limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED at £2.8b based on Net Assets of £1.2b and 2.39x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Glaxosmithkline Research & Development Limited Overview
Glaxosmithkline Research & Development Limited is a live company located in london, WC1A 1DG with a Companies House number of 00835139. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in January 1965, it's largest shareholder is glaxo group ltd with a 100% stake. Glaxosmithkline Research & Development Limited is a mature, mega sized company, Pomanda has estimated its turnover at £1.5b with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Glaxosmithkline Research & Development Limited Health Check
Pomanda's financial health check has awarded Glaxosmithkline Research & Development Limited a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 2 areas for improvement. Company Health Check FAQs
5 Strong
2 Regular
2 Weak
Size
annual sales of £1.5b, make it larger than the average company (£4.4m)
£1.5b - Glaxosmithkline Research & Development Limited
£4.4m - Industry AVG
Growth
3 year (CAGR) sales growth of 5%, show it is growing at a slower rate (6.4%)
5% - Glaxosmithkline Research & Development Limited
6.4% - Industry AVG
Production
with a gross margin of 44%, this company has a comparable cost of product (44%)
44% - Glaxosmithkline Research & Development Limited
44% - Industry AVG
Profitability
an operating margin of 5.6% make it more profitable than the average company (3.2%)
5.6% - Glaxosmithkline Research & Development Limited
3.2% - Industry AVG
Employees
with 3328 employees, this is above the industry average (49)
3328 - Glaxosmithkline Research & Development Limited
49 - Industry AVG
Pay Structure
on an average salary of £167.4k, the company has a higher pay structure (£61.8k)
£167.4k - Glaxosmithkline Research & Development Limited
£61.8k - Industry AVG
Efficiency
resulting in sales per employee of £435.8k, this is more efficient (£108.9k)
£435.8k - Glaxosmithkline Research & Development Limited
£108.9k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Research & Development Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 102 days, this is slower than average (46 days)
102 days - Glaxosmithkline Research & Development Limited
46 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Research & Development Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Research & Development Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 45.4%, this is a similar level of debt than the average (42.6%)
45.4% - Glaxosmithkline Research & Development Limited
42.6% - Industry AVG
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED financials
Glaxosmithkline Research & Development Limited's latest turnover from December 2023 is £1.5 billion and the company has net assets of £1.2 billion. According to their latest financial statements, Glaxosmithkline Research & Development Limited has 3,328 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 1,450,454,000 | 1,428,563,000 | 1,379,524,000 | 1,262,874,000 | 1,102,779,000 | 1,049,914,000 | 1,077,287,000 | 992,283,000 | 1,015,300,000 | 1,010,257,000 | 1,007,830,000 | 1,025,449,000 | 1,075,393,000 | 1,439,683,000 | 1,246,330,000 |
| Other Income Or Grants | 0 | ||||||||||||||
| Cost Of Sales | 933,563,000 | ||||||||||||||
| Gross Profit | 76,694,000 | ||||||||||||||
| Admin Expenses | 0 | ||||||||||||||
| Operating Profit | 80,447,000 | 98,595,000 | 69,289,000 | 104,591,000 | 86,654,000 | 89,387,000 | 92,598,000 | 71,441,000 | 61,832,000 | 76,694,000 | 79,950,000 | 63,026,000 | 31,550,000 | 133,506,000 | 37,792,000 |
| Interest Payable | 407,000 | 373,000 | 249,000 | 96,000 | 93,000 | 0 | 0 | 60,000 | 0 | 0 | 0 | 8,000 | 36,000 | 46,000 | |
| Interest Receivable | 34,531,000 | 11,330,000 | 29,000 | 731,000 | 3,900,000 | 2,773,000 | 736,000 | 1,347,000 | 851,000 | 389,000 | 18,000 | 2,432,000 | 3,332,000 | 2,061,000 | 1,873,000 |
| Pre-Tax Profit | 114,571,000 | 109,552,000 | 69,069,000 | 105,226,000 | 90,461,000 | 92,160,000 | 93,334,000 | 72,728,000 | 62,683,000 | 77,083,000 | 79,968,000 | 65,081,000 | 34,874,000 | 134,257,000 | 39,619,000 |
| Tax | -34,583,000 | -7,088,000 | -24,144,000 | -32,606,000 | -18,328,000 | -19,037,000 | -18,635,000 | -9,048,000 | -3,927,000 | -13,746,000 | 804,000 | 1,639,000 | 12,268,000 | -14,915,000 | 11,159,000 |
| Profit After Tax | 79,988,000 | 102,464,000 | 44,925,000 | 72,620,000 | 72,133,000 | 73,123,000 | 74,699,000 | 63,680,000 | 58,756,000 | 63,337,000 | 80,772,000 | 66,720,000 | 47,142,000 | 119,342,000 | 50,778,000 |
| Dividends Paid | 0 | 400,000,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 350,000,000 | 0 | 0 |
| Retained Profit | 79,988,000 | -297,536,000 | 44,925,000 | 72,620,000 | 72,133,000 | 73,123,000 | 74,699,000 | 63,680,000 | 58,756,000 | 63,337,000 | 80,772,000 | 66,720,000 | -302,858,000 | 119,342,000 | 50,778,000 |
| Employee Costs | 557,119,000 | 458,715,000 | 448,589,000 | 457,993,000 | 453,811,000 | 415,967,000 | 400,426,000 | 398,095,000 | 378,863,000 | 366,748,000 | 393,886,000 | 344,761,000 | 0 | 0 | 411,670,000 |
| Number Of Employees | 3,328 | 3,245 | 3,259 | 3,260 | 3,317 | 3,439 | 3,831 | 3,803 | 3,692 | 3,571 | 3,046 | 3,314 | 3,655 | 4,303 | 4,645 |
| EBITDA* | 196,964,000 | 201,862,000 | 178,181,000 | 206,136,000 | 175,849,000 | 163,205,000 | 156,646,000 | 188,587,000 | 144,456,000 | 136,686,000 | 151,218,000 | 142,196,000 | 122,030,000 | 398,105,000 | 231,128,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 520,602,000 | 519,454,000 | 505,635,000 | 536,561,000 | 549,246,000 | 550,055,000 | 569,011,000 | 546,820,000 | 640,334,000 | 669,600,000 | 674,948,000 | 680,504,000 | 720,385,000 | 814,878,000 | 1,045,429,000 |
| Intangible Assets | 181,573,000 | 168,554,000 | 111,477,000 | 90,608,000 | 91,322,000 | 88,496,000 | 89,016,000 | 94,017,000 | 51,424,000 | 27,011,000 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 5,914,000 | 0 | 18,488,000 | 20,361,000 | 21,637,000 | 23,565,000 | 27,641,000 | 27,301,000 | 17,024,000 | 55,000 | 55,000 | 55,000 | 432,000 | 432,000 | 1,706,000 |
| Debtors (Due After 1 year) | 818,266,000 | 736,668,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12,006,000 | 13,156,000 | 0 | 3,733,000 | 2,582,000 | 2,453,000 |
| Total Fixed Assets | 1,526,355,000 | 1,424,676,000 | 635,600,000 | 647,530,000 | 662,205,000 | 662,116,000 | 685,668,000 | 668,138,000 | 708,782,000 | 708,672,000 | 688,159,000 | 680,559,000 | 724,550,000 | 817,892,000 | 1,049,588,000 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,000 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 601,420,000 | 425,569,000 | 1,362,852,000 | 1,498,106,000 | 1,255,658,000 | 1,156,154,000 | 987,448,000 | 940,107,000 | 856,815,000 | 1,441,999,000 | 742,988,000 | 687,586,000 | 924,837,000 | 1,165,054,000 | 830,401,000 |
| Misc Debtors | 51,707,000 | 69,542,000 | 27,421,000 | 57,369,000 | 68,930,000 | 5,523,000 | 7,292,000 | 6,316,000 | 60,808,000 | 54,891,000 | 24,514,000 | 45,953,000 | 35,654,000 | 49,958,000 | 43,969,000 |
| Cash | 0 | 0 | 0 | 0 | 0 | 2,000 | 0 | 22,000 | 6,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| misc current assets | 0 | 0 | 18,813,000 | 0 | 0 | 36,403,000 | 41,510,000 | 35,785,000 | 22,691,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 653,127,000 | 495,111,000 | 1,409,086,000 | 1,555,475,000 | 1,324,588,000 | 1,198,082,000 | 1,036,250,000 | 982,230,000 | 940,320,000 | 1,496,892,000 | 767,502,000 | 733,539,000 | 960,491,000 | 1,215,012,000 | 874,370,000 |
| total assets | 2,179,482,000 | 1,919,787,000 | 2,044,686,000 | 2,203,005,000 | 1,986,793,000 | 1,860,198,000 | 1,721,918,000 | 1,650,368,000 | 1,649,102,000 | 2,205,564,000 | 1,455,661,000 | 1,414,098,000 | 1,685,041,000 | 2,032,904,000 | 1,923,958,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 72,000 | 0 | 0 | 14,000 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 227,505,000 | 170,028,000 | 181,631,000 | 203,951,000 | 209,031,000 | 165,901,000 | 153,922,000 | 155,549,000 | 113,466,000 | 123,558,000 | 77,202,000 | 59,736,000 | 78,753,000 | 66,658,000 | 65,353,000 |
| Group/Directors Accounts | 480,845,000 | 313,741,000 | 183,710,000 | 353,182,000 | 232,607,000 | 245,307,000 | 201,211,000 | 188,651,000 | 294,576,000 | 886,156,000 | 219,623,000 | 285,234,000 | 573,181,000 | 497,485,000 | 581,537,000 |
| other short term finances | 0 | 0 | 0 | 0 | 544,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 698,000 | 881,000 | 938,000 | 917,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 491,000 | 685,000 |
| other current liabilities | 263,784,000 | 288,443,000 | 176,222,000 | 190,270,000 | 146,615,000 | 124,029,000 | 104,631,000 | 107,803,000 | 89,726,000 | 93,700,000 | 116,605,000 | 104,168,000 | 107,456,000 | 184,114,000 | 58,713,000 |
| total current liabilities | 972,832,000 | 773,093,000 | 542,501,000 | 748,320,000 | 588,797,000 | 535,237,000 | 459,836,000 | 452,003,000 | 497,768,000 | 1,103,428,000 | 413,430,000 | 449,138,000 | 759,390,000 | 748,748,000 | 706,288,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 14,790,000 | 15,315,000 | 5,878,000 | 3,641,000 | 4,102,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 476,000 |
| Accruals and Deferred Income | 1,480,000 | 1,574,000 | 1,668,000 | 1,762,000 | 1,856,000 | 1,949,000 | 1,949,000 | 2,043,000 | 2,138,000 | 2,231,000 | 2,325,000 | 2,419,000 | 2,512,000 | 2,606,000 | 3,082,000 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 537,000 | 1,816,000 | 3,131,000 |
| provisions | 0 | 19,413,000 | 86,711,000 | 86,279,000 | 101,516,000 | 104,617,000 | 114,875,000 | 125,698,000 | 142,448,000 | 151,913,000 | 155,251,000 | 158,658,000 | 185,439,000 | 239,713,000 | 290,302,000 |
| total long term liabilities | 16,270,000 | 36,302,000 | 94,257,000 | 91,682,000 | 107,474,000 | 106,566,000 | 116,824,000 | 127,741,000 | 144,586,000 | 154,144,000 | 157,576,000 | 161,077,000 | 188,488,000 | 244,135,000 | 296,991,000 |
| total liabilities | 989,102,000 | 809,395,000 | 636,758,000 | 840,002,000 | 696,271,000 | 641,803,000 | 576,660,000 | 579,744,000 | 642,354,000 | 1,257,572,000 | 571,006,000 | 610,215,000 | 947,878,000 | 992,883,000 | 1,003,279,000 |
| net assets | 1,190,380,000 | 1,110,392,000 | 1,407,928,000 | 1,363,003,000 | 1,290,522,000 | 1,218,395,000 | 1,145,258,000 | 1,070,624,000 | 1,006,748,000 | 947,992,000 | 884,655,000 | 803,883,000 | 737,163,000 | 1,040,021,000 | 920,679,000 |
| total shareholders funds | 1,190,380,000 | 1,110,392,000 | 1,407,928,000 | 1,363,003,000 | 1,290,522,000 | 1,218,395,000 | 1,145,258,000 | 1,070,624,000 | 1,006,748,000 | 947,992,000 | 884,655,000 | 803,883,000 | 737,163,000 | 1,040,021,000 | 920,679,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 80,447,000 | 98,595,000 | 69,289,000 | 104,591,000 | 86,654,000 | 89,387,000 | 92,598,000 | 71,441,000 | 61,832,000 | 76,694,000 | 79,950,000 | 63,026,000 | 31,550,000 | 133,506,000 | 37,792,000 |
| Depreciation | 63,560,000 | 74,342,000 | 87,843,000 | 57,611,000 | 58,131,000 | 51,868,000 | 45,585,000 | 102,844,000 | 71,093,000 | 59,992,000 | 71,268,000 | 79,170,000 | 90,480,000 | 264,599,000 | 193,336,000 |
| Amortisation | 52,957,000 | 28,925,000 | 21,049,000 | 43,934,000 | 31,064,000 | 21,950,000 | 18,463,000 | 14,302,000 | 11,531,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -34,583,000 | -7,088,000 | -24,144,000 | -32,606,000 | -18,328,000 | -19,037,000 | -18,635,000 | -9,048,000 | -3,927,000 | -13,746,000 | 804,000 | 1,639,000 | 12,268,000 | -14,915,000 | 11,159,000 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 239,614,000 | -158,494,000 | -165,202,000 | 230,887,000 | 162,911,000 | 166,937,000 | 48,317,000 | 28,800,000 | -591,275,000 | 728,240,000 | 47,119,000 | -230,685,000 | -253,370,000 | 340,771,000 | 876,823,000 |
| Creditors | 57,477,000 | -11,603,000 | -22,320,000 | -5,080,000 | 43,130,000 | 11,979,000 | -1,627,000 | 42,083,000 | -10,092,000 | 46,356,000 | 17,466,000 | -19,017,000 | 12,095,000 | 1,305,000 | 65,353,000 |
| Accruals and Deferred Income | -24,753,000 | 112,127,000 | -14,142,000 | 43,561,000 | 22,493,000 | 19,398,000 | -3,266,000 | 17,982,000 | -4,067,000 | -22,999,000 | 12,343,000 | -3,381,000 | -76,752,000 | 124,925,000 | 61,795,000 |
| Deferred Taxes & Provisions | -19,413,000 | -67,298,000 | 432,000 | -15,237,000 | -3,101,000 | -10,258,000 | -10,823,000 | -16,750,000 | -9,465,000 | -3,338,000 | -3,407,000 | -26,781,000 | -54,274,000 | -50,589,000 | 290,302,000 |
| Cash flow from operations | -63,922,000 | 386,494,000 | 283,209,000 | -34,113,000 | 57,132,000 | -1,650,000 | 73,978,000 | 194,054,000 | 708,180,000 | -585,281,000 | 131,305,000 | 325,341,000 | 268,737,000 | 118,060,000 | -217,086,000 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 5,914,000 | -18,488,000 | -1,873,000 | -1,276,000 | -1,928,000 | -4,076,000 | 340,000 | 10,277,000 | 16,969,000 | 0 | 0 | -377,000 | 0 | -1,274,000 | 1,706,000 |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 167,104,000 | 130,031,000 | -169,472,000 | 120,575,000 | -12,700,000 | 44,096,000 | 12,560,000 | -105,925,000 | -591,580,000 | 666,533,000 | -65,611,000 | -287,947,000 | 75,696,000 | -84,052,000 | 581,537,000 |
| Other Short Term Loans | 0 | 0 | 0 | -544,000 | 544,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | -708,000 | 9,380,000 | 2,258,000 | 456,000 | 4,102,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -491,000 | -670,000 | 1,161,000 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -537,000 | -1,279,000 | -1,315,000 | 3,131,000 |
| share issue | |||||||||||||||
| interest | 34,124,000 | 10,957,000 | -220,000 | 635,000 | 3,807,000 | 2,773,000 | 736,000 | 1,287,000 | 851,000 | 18,000 | 2,432,000 | 3,324,000 | 2,025,000 | 1,827,000 | |
| cash flow from financing | 200,520,000 | 150,368,000 | -167,434,000 | 120,983,000 | -4,253,000 | 46,883,000 | 13,231,000 | -104,442,000 | -590,729,000 | -65,593,000 | -286,052,000 | 77,250,000 | -84,012,000 | 1,457,557,000 | |
| cash and cash equivalents | |||||||||||||||
| cash | 0 | 0 | 0 | 0 | -2,000 | 2,000 | -22,000 | 16,000 | 6,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | -72,000 | 72,000 | 0 | -14,000 | 14,000 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | -2,000 | 74,000 | -94,000 | 16,000 | 20,000 | -14,000 | 0 | 0 | 0 | 0 | 0 |
glaxosmithkline research & development limited Credit Report and Business Information
Glaxosmithkline Research & Development Limited Competitor Analysis
Perform a competitor analysis for glaxosmithkline research & development limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mega companies, companies in WC1A area or any other competitors across 12 key performance metrics.
glaxosmithkline research & development limited Ownership
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED group structure
Glaxosmithkline Research & Development Limited has no subsidiary companies.
Ultimate parent company
2 parents
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
00835139
glaxosmithkline research & development limited directors
Glaxosmithkline Research & Development Limited currently has 6 directors. The longest serving directors include Mr Jerome Andries (Apr 2018) and Mr Graham Rivers (Sep 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Jerome Andries | United Kingdom | 55 years | Apr 2018 | - | Director |
| Mr Graham Rivers | United Kingdom | 53 years | Sep 2023 | - | Director |
| Mr Christopher Pickering | United Kingdom | 51 years | May 2024 | - | Director |
| Dr Kaivan Khavandi | United Kingdom | 39 years | May 2024 | - | Director |
| Mrs Demet Gurunlu Russ | United Kingdom | 53 years | Jun 2024 | - | Director |
| Mr Aidan Lynch | United Kingdom | 60 years | Aug 2024 | - | Director |
P&L
December 2023turnover
1.5b
+2%
operating profit
80.4m
-18%
gross margin
44%
-5.98%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
1.2b
+0.07%
total assets
2.2b
+0.14%
cash
0
0%
net assets
Total assets minus all liabilities
glaxosmithkline research & development limited company details
company number
00835139
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
January 1965
age
59
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
glaxo research and development limited (December 2001)
glaxo group research limited (January 1994)
accountant
-
auditor
DELOITTE LLP
address
79 new oxford street, london, WC1A 1DG
Bank
-
Legal Advisor
-
glaxosmithkline research & development limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to glaxosmithkline research & development limited. Currently there are 0 open charges and 1 have been satisfied in the past.
glaxosmithkline research & development limited Companies House Filings - See Documents
| date | description | view/download |
|---|
